Literature DB >> 9174191

Disposition of atovaquone in humans.

P E Rolan1, A J Mercer, E Tate, I Benjamin, J Posner.   

Abstract

Atovaquone is an antiprotozoal compound with good in vitro stability against metabolic inactivation. Previous human studies which did not involve radiolabelling had not accounted for a substantial proportion of the dose. The possible metabolism of atovaquone in men was examined in a radiolabelling study involving four healthy male volunteers. Radioactivity was eliminated almost exclusively via the feces. All radioactivity in plasma, urine, and feces was accounted for by atovaquone, with no evidence of metabolites. Radiolabelled atovaquone was administered to a patient with an indwelling biliary tube after surgery. Biliary radioactivity was approximately 10- to 40-fold higher than that in plasma and was accounted for by atovaquone. Atovaquone is not significantly metabolized in humans but is excreted into bile against a high concentration gradient.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174191      PMCID: PMC163907          DOI: 10.1128/AAC.41.6.1319

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii.

Authors:  J Huskinson-Mark; F G Araujo; J S Remington
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

2.  Examination of some factors responsible for a food-induced increase in absorption of atovaquone.

Authors:  P E Rolan; A J Mercer; B C Weatherley; T Holdich; H Meire; R W Peck; G Ridout; J Posner
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

3.  Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.

Authors:  W Hughes; G Leoung; F Kramer; S A Bozzette; S Safrin; P Frame; N Clumeck; H Masur; D Lancaster; C Chan
Journal:  N Engl J Med       Date:  1993-05-27       Impact factor: 91.245

4.  Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro.

Authors:  D J Hammond; J R Burchell; M Pudney
Journal:  Mol Biochem Parasitol       Date:  1985-01       Impact factor: 1.759

  4 in total
  15 in total

1.  In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum.

Authors:  S Gupta; M M Thapar; W H Wernsdorfer; A Björkman
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 2.  Antiparasitic agent atovaquone.

Authors:  Aaron L Baggish; David R Hill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.

Authors:  K Na-Bangchang; C Manyando; R Ruengweerayut; D Kioy; M Mulenga; G B Miller; J Konsil
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

4.  Fetomaternal and Pediatric Toxoplasmosis.

Authors:  Helieh S Oz
Journal:  J Pediatr Infect Dis       Date:  2017-12       Impact factor: 0.293

5.  Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers.

Authors:  Ryohkan Funakoshi; Yukana Tomoda; Toshiyuki Kudo; Kenichi Furihata; Hiroyuki Kusuhara; Kiyomi Ito
Journal:  Br J Clin Pharmacol       Date:  2019-04-16       Impact factor: 4.335

6.  Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.

Authors:  Eva Maria Staehli Hodel; Chantal Csajka; Frédéric Ariey; Monia Guidi; Abdunoor Mulokozi Kabanywanyi; Socheat Duong; Laurent Arthur Decosterd; Piero Olliaro; Hans-Peter Beck; Blaise Genton
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

7.  Microbial Metabolism of Atovaquone and Cytotoxicity of the Produced Phase I Metabolite.

Authors:  Eliane de Oliveira Silva; Natália Dos Santos Gonçalves; Raquel Alves Dos Santos; Niege Araçari Jacometti Cardoso Furtado
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

Review 8.  Malaria prophylaxis in patients with renal impairment: a review.

Authors:  Sabine Amet; Sarah Zimner-Rapuch; Vincent Launay-Vacher; Nicolas Janus; Gilbert Deray
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

Review 9.  BDDCS, the Rule of 5 and drugability.

Authors:  Leslie Z Benet; Chelsea M Hosey; Oleg Ursu; Tudor I Oprea
Journal:  Adv Drug Deliv Rev       Date:  2016-05-13       Impact factor: 15.470

10.  A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs.

Authors:  Eva Maria Hodel; Serej D Ley; Weihong Qi; Frédéric Ariey; Blaise Genton; Hans-Peter Beck
Journal:  Malar J       Date:  2009-12-09       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.